



DRAFT

NorCal SOT Fall Symposium 2018

A New Hope: Nonclinical Challenges in the Burgeoning Field of Gene Therapy

October 25, 2018

South San Francisco Conference Center, 255 South Airport Boulevard,
South San Francisco, CA 94080

| Morning Session | |
|---------------------|--|
| 7:30 am – 8:30 am | Registration & Breakfast |
| 8:30 am – 8:45 am | Opening Message from the NorCal SOT President <i>Kathryn Page, PhD, DABT, Toxicologist, Product Safety, The Clorox Company</i> |
| 8:45 am – 9:30 am | Presentation 1: Gene Therapy, Tailored Therapeutics and the Rise of Homo Deus <i>Kevin Morris, PhD, Professor and Associate Director, Center for Gene Therapy, Backman City of Hope</i> |
| 9:30 am – 10:15 am | Presentation 2: Title TBD (Topic – Regulatory Considerations) <i>Ying Huang, PhD, FDA/CBER/OTAT/DCEPT, US Food and Drug Administration</i> |
| 10:15 am – 10:30 am | Coffee Break |
| 10:30 am – 11:15 am | Presentation 3: 10 Years of Gene Therapy Drug Development; Lessons Learned from the NHLBI Gene Therapy Program <i>Jacob McDonald, PhD, Senior Scientist, Chief Scientific Officer, Lovelace Biomedical</i> |
| 11:15 am – 12:00 pm | Presentation 4: Nonclinical Development within Gene Therapy Programs – Unique Opportunities Require Unique (and Dynamic) Approaches <i>Michael Templin, PhD, DABT, Senior Principal Scientific Advisor, Charles River Laboratories</i> |
| 12:00 pm – 1:20 pm | Lunch Break: Lunch with Experts |
| Afternoon Session | |
| 1:20 pm – 1:35 pm | Chapter Announcements and Acknowledgements |
| 1:35 pm – 2:20 pm | Presentation 5: Nonclinical Studies Evaluating Genome Editing Therapeutics <i>Kathleen Meyer, MPH, PhD, DABT, Vice President, Nonclinical Development, Sangamo Therapeutics, Inc.</i> |
| 2:20 pm – 3:05 pm | Presentation 6: Oligonucleotides as Therapeutics: The Past, Present and Future <i>Sushmita Chanda, PhD, DABT, Vice President, Preclinical Development, Alios BioPharma</i> |
| 3:05 pm – 3:20 pm | Coffee Break |
| 3:20 pm – 4:00 pm | Presentation 7: Clinical Manufacturing of Gene Corrected Human Regulatory T Cells <i>Jonathan Esensten, MD, PhD, Assistant Adjunct Professor, Dept. of Laboratory Medicine, University of California, San Francisco (UCSF)</i> |
| 4:00 pm – 4:05 pm | Closing Remarks |
| 4:05 pm – 5:30 pm | Reception & Networking |

DIRECTIONS TO SSF CONFERENCE CENTER